ArticleResearch and practice in thrombosis and haemostasis2026
Prognostic value of von Willebrand factor and ADAMTS-13 in patients with sepsis-induced coagulopathy.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The von Willebrand factor (VWF)- a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS-13) axis may contribute to microvascular thrombosis and poor outcomes in sepsis-induced coagulopathy (SIC). Objectives: The aim of this study was to characterize the VWF-ADAMTS-13 axis in SIC and evaluate whether VWF/ADAMTS-13 ratios are associated with SIC diagnosis and 28-day mortality. Methods: In this prospective cohort study, 240 adult patients in the intensive care unit meeting Sepsis-3 criteria were consecutively enrolled at the First Hospital of Jilin University from February to October 2025. VWF antigen, factor VIII, ADAMTS-13 activity, and ADAMTS-13 antigen were measured within 24 hours of enrollment. VWF/ADAMTS-13 activity and antigen ratios were calculated. International Society on Thrombosis and Haemostasis SIC and overt disseminated intravascular coagulation scores were derived. The primary outcome was 28-day all-cause mortality. Associations were assessed using multivariable logistic regression, receiver operating characteristic curve analysis, and Kaplan-Meier survival analysis. Results: Overall, 152 patients (63.3%) met SIC criteria. Compared with non-SIC patients, SIC patients had lower ADAMTS-13 activity, higher VWF/ADAMTS-13 activity and antigen ratios, and higher 28-day mortality. After exclusion of variables included in the SIC score, VWF-ADAMTS-13 biomarkers were not independently associated with SIC diagnosis. Among patients with SIC, nonsurvivors had lower ADAMTS-13 activity and antigen levels but higher VWF/ADAMTS-13 ratios than survivors. In adjusted models, the VWF/ADAMTS-13 activity and antigen ratios were independently associated with 28-day mortality, with modest discriminatory ability (areas under the curve of 0.66 and 0.65, respectively). Mortality increased across VWF/ADAMTS-13 activity ratio quartiles. Conclusion: VWF/ADAMTS-13 ratios are not independent diagnostic markers for SIC but are independently associated with 28-day mortality in established SIC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.